Skip to main content

Table 2 Outcomes and efficacy of mobilization in 39 patients with high-risk non-Hodgkin’s lymphoma

From: Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma

Parameter

All patients (n = 39)

R-CHOP (n = 14)

CHOP (n = 25)

P value

Time from mobilization chemotherapy to rhG-CSF support (days)a

9 (6–15)

12.5 (9–15)

12 (6–15)

0.082

Duration of rhG-CSF support (days)a

5 (3–10)

5 (3–9)

5 (4–10)

0.343

Time from mobilization chemotherapy to apheresis (days)a

16 (12–20)

16.5 (15–18)

16 (12–20)

0.032

Percentage of CD34+ cells in peripheral blood on the first day of apheresis (%)a

2.43 (0.36–7.50)

1.35 (0.36–3.41)

3.14 (1.14–7.50)

0.002

Peripheral blood WBC count on the first day of apheresis (×109/L)a

14.30 (3.55–43.20)

10.35 (3.55–43.20)

17.15 (5.56–41.60)

0.031

Number of apheresis proceduresa

1 (1–3)

1 (1–2)

1 (1–3)

0.593

CD34+ cells collected on day 1 (×106 cells/kg body weight)a

5.79 (0.40–18.50)

4.83 (1.03–8.11)

7.07 (0.40–18.50)

0.016

CD34+ cells collected in total (×106 cells/kg body weight)a

7.01 (1.49–28.39)

5.01 (1.49–13.40)

8.25 (1.61–28.39)

0.005

CD34+ cells collected per apheresis (×106 cells/kg body weight)a

5.97 (0.75–18.50)

4.83 (0.75–8.11)

7.31 (0.81–18.50)

0.014

Optimal mobilization of CD34+ cell collection [cases (%)]

27 (69.2)

7 (50.0)

20 (80.0)

0.075

Successful mobilization of CD34+ cells [cases (%)]

37 (94.5)

13 (92.9)

24 (96.0)

1.000

  1. rhG-CSF recombinant human granulocyte colony-stimulating factor, WBC white blood cell. Other abbreviations as in Table 1
  2. aThe values are presented as median followed by range in parentheses; other values are presented as the number of patients followed by percentages in parentheses